[fam-] trastuzumab deruxtecan (DS-8201) - Daiichi Sankyo, AstraZeneca
DS-8201: Data from P3 DESTINY-Breast04 trial (NCT03734029) for HER2-low, unresectable and/or metastatic breast cancer in 2021 (AstraZeneca) - Oct 24, 2019 - Q3 2019 Results: Data from P2 DESTINY-Gastric01 trial (NCT03329690) for HER2-overexpressing advanced gastric cancer in H1 2020 
P2 data • P3 data
https://www.astrazeneca.com/content/dam/az/PDF/2019/q3/Year-to-date_and_Q3_2019_Results_clinical_trials_appendix.pdf
 
Oct 24, 2019
 
 
ee983c39-4840-494f-bb0a-6d8a16a350a4.jpg